Dr Jo Perry
Localised production of growth hormone (GH) is detectable in a variety of different human cancers, including breast cancer, and this is associated with an increased risk of metastasis and reduced survival for breast cancer patients.
SHON as a novel biomarker predicting endocrine therapy response in breast cancer
Dr Dong Xu-Lui
Breast cancer affects 1 in 9 New Zealand women. Anti-estrogens such as tamoxifen have been used to treat estrogen receptor positive (ER+) breast cancer and reduce the annual death rate by approximately one third.
Targeting the immune response to improve outcomes in ER+ve breast cancer
Dr Anita Dunbier
Every year, more than 2000 New Zealand women are diagnosed with oestrogen receptor positive breast cancer.